Uncategorised

Uncategorised

Omalizumab biosimilar by Mabpharm for Chronic Urticaria Or Hives: Likelihood of Approval

Omalizumab biosimilar is under clinical development by Mabpharm and currently in Phase III for Chronic Urticaria Or Hives. According to…

Uncategorised

Iptacopan hydrochloride by Novartis for Myasthenia Gravis: Likelihood of Approval

Uncategorised

Sirolimus by Biodexa Pharmaceuticals for Prostate Cancer: Likelihood of Approval

Uncategorised

GCC-4001 by Artiva Biotherapeutics for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

Uncategorised

Trientine hydrochloride by Innolife for Systolic Heart Failure: Likelihood of Approval

Uncategorised

Risk adjusted net present value: What is the current valuation of Milestone Pharmaceuticals’s Etripamil?

Uncategorised

Risk adjusted net present value: What is the current valuation of AstraZeneca’s Vemircopan?

Uncategorised

CMN-005 by CoImmune for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval

Uncategorised

Alpha-1 proteinase inhibitor (human) second generation by Kamada Pharmaceuticals for Alpha-1 Antitrypsin Deficiency (A1AD): Likelihood of Approval

Uncategorised

Alectinib by F. Hoffmann-La Roche for Central Nervous System (CNS) Tumor: Likelihood of Approval

Uncategorised

Ixazomib citrate by Millennium Pharmaceuticals for Relapsing Remitting Multiple Sclerosis (RRMS): Likelihood of Approval

Uncategorised

SON-DP by Qurgen for Metastatic Colorectal Cancer: Likelihood of Approval

Uncategorised

Safinamide mesylate by Zambon Co for Drug-Induced Dyskinesia: Likelihood of Approval

Uncategorised

MEMANT-3310 by Antabio for Acinetobacter Infections: Likelihood of Approval

Uncategorised

Risk adjusted net present value: What is the current valuation of BioAtla’s Evalstotug?

Uncategorised

Risk adjusted net present value: What is the current valuation of Disc Medicine’s DISC-0974?

Uncategorised

AZD-9574 by AstraZeneca for Bladder Cancer: Likelihood of Approval

Uncategorised

AL-8326 by Advenchen Laboratories for Breast Cancer: Likelihood of Approval

Uncategorised

Everolimus by Novartis for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Uncategorised

Itacitinib adipate by Incyte for Bronchiolitis Obliterans: Likelihood of Approval

Uncategorised

MRNA-1083 by Moderna for Influenza A Virus, H3N2 Subtype Infections: Likelihood of Approval

Uncategorised

IBI-334 by Innovent Biologics for Head And Neck Cancer Squamous Cell Carcinoma: Likelihood of Approval

Uncategorised

Polzastobart by Concentra Biosciences for Head And Neck Cancer Squamous Cell Carcinoma: Likelihood of Approval

Uncategorised

Risk adjusted net present value: What is the current valuation of Incyte’s Parsaclisib?

Uncategorised

NMDP-02 by NMD Pharma for Spinal Muscular Atrophy (SMA): Likelihood of Approval

Uncategorised

TAC-100 by Triumvira Immunologics for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Uncategorised

Arsenic trioxide by Syros Pharmaceuticals for Acute Promyelocytic Leukemia: Likelihood of Approval

Uncategorised

ATRN-119 by Aprea Therapeutics for Ovarian Cancer: Likelihood of Approval

Uncategorised

DS-9606a by Daiichi Sankyo for Metastatic Ovarian Cancer: Likelihood of Approval

Uncategorised

Eflornithine by Panbela Therapeutics for Gastric Cancer: Likelihood of Approval

Uncategorised

HCW-9218 by HCW Biologics for Breast Cancer: Likelihood of Approval

Uncategorised

Elimusertib by Bayer for Ovarian Cancer: Likelihood of Approval

Uncategorised

NKTR-255 by Nektar Therapeutics for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

Uncategorised

Sirolimus albumin-bound by Aadi Bioscience for Bladder Cancer: Likelihood of Approval

Uncategorised

Aminolevulinic acid hydrochloride by Photonamic for Glioblastoma Multiforme (GBM): Likelihood of Approval

Uncategorised

How did hiring in the French pharma industry perform in Q3 2023?

Uncategorised

How did hiring in the French pharma industry perform in Q3 2023?

Uncategorised

How did hiring in the French pharma industry perform in Q3 2023?

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Pharma Technology Focus : Pharmaceutical Technology Focus (monthly)

Thematic Take (monthly)

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close